Decision: Favourable

Study Title:

A Phase 3 Study to Evaluate Zimberelimab (AB122) Combined with Domvanalimab (AB154) Compared to Pembrolizumab in Front-Line, PD-L1- High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • NREC Code:


  • Decision:


  • Meeting Date:


  • Study Type:

    CT application

  • Principal Investigator:

    Dr. Jarushka Naidoo

  • PI Institution:

    Beaumont Hospital

  • Sponsor:

    Arcus Biosciences, Inc.

Scroll to Top
Skip to content